Ligand Pharmaceuticals (STU:LGDN) Cyclically Adjusted PB Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:LGDN Ligand Pharmaceuticals Inc STU:LGDN
77 GF Score
Price €246.00
GF Value €162.90
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Ligand Pharmaceuticals Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Ligand Pharmaceuticals  (STU:LGDN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Ligand Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms


Ligand Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Ligand Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ligand Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Ligand Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.34 2.50 2.21 3.05 4.30

Ligand Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.55 3.82 4.17 4.23 6.66

STU:LGDN vs CRSP, DFTX, XENE: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Ligand Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ligand Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ligand Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Ligand Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


STU:LGDN
77GF Score
Ligand Pharmaceuticals Inc STU:LGDN
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ligand Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Ligand Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Ligand Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=42.482/333.9520*333.9520
=42.482

Current CPI (Jun. 2026) = 333.9520.

Ligand Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201609 14.402 241.428 19.921
201612 15.475 241.432 21.405
201703 16.558 243.801 22.681
201706 16.041 244.955 21.869
201709 16.167 246.819 21.874
201712 15.743 246.524 21.326
201803 18.364 249.554 24.575
201806 25.165 251.989 33.350
201809 28.549 252.439 37.768
201812 23.629 251.233 31.409
201903 48.913 254.202 64.258
201906 47.164 256.143 61.491
201909 44.423 256.759 57.778
201912 40.628 256.974 52.798
202003 37.585 258.115 48.628
202006 38.504 257.797 49.878
202009 36.982 260.280 47.450
202012 36.063 260.474 46.236
202103 38.109 264.877 48.047
202106 39.771 271.696 48.884
202109 41.940 274.310 51.059
202112 43.066 278.802 51.585
202203 42.280 287.504 49.111
202206 45.462 296.311 51.237
202209 49.323 296.808 55.496
202212 33.027 296.797 37.162
202303 34.720 301.836 38.414
202306 35.122 305.109 38.442
202309 36.211 307.789 39.289
202312 36.142 306.746 39.348
202403 41.664 312.332 44.548
202406 39.955 314.175 42.470
202409 40.176 315.301 42.553
202412 41.975 315.605 44.415
202503 38.207 319.799 39.898
202506 36.362 322.561 37.646
202509 41.140 324.800 42.299
202512 43.801 324.054 45.139
202603 43.216 330.213 43.705
202606 42.482 333.952 42.482

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Ligand Pharmaceuticals (STU:LGDN) Overvalued in 2026?

Based on GuruFocus' analysis, Ligand Pharmaceuticals stock appears to be overvalued. The current stock price of €246.00 is trading 51% above its estimated GF Value™ of €162.90. GuruFocus considers Ligand Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:LGDN:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €162.90 vs. price of €246.00 (51% above fair value)
  • GF Score™: 77/100 with 2 warning signs

No single metric tells the full story. See the STU:LGDN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ligand Pharmaceuticals Business Description

Other Exchanges LGND:USALGDN:Germany
Address 555 Heritage Drive, Suite 200, Jupiter, FL, USA, 33458
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
77GF Score

Get the complete analysis for STU:LGDN

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€246.00
Price
€162.90
GF Value